N
INDV icon

Natixis’s Indivior Pharmaceuticals INDV Stock Holding History

Natixis’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17M Buy
+126,100
New +$4.57M 0.02% 430

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis's INDV Position: Q2 2026 in Review

Natixis opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 126,100 shares worth $5.17M. The stake represents 0.02% of the portfolio and ranks #430 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Natixis held 126,100 shares of Indivior Pharmaceuticals worth $5.17M as of Q2 2026.
  • Indivior Pharmaceuticals was a new Natixis position in Q2 2026.
  • Indivior Pharmaceuticals made up 0.02% of Natixis's portfolio in Q2 2026, its #430 holding.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.